Hepatic stellate cells (Hscs) have been identified as the main fibrogenic cell type in the liver. Hence, efforts to understand hepatic fibrogenesis and to develop treatment strategies have focused on this cell type. Hsc isolation, originally developed in rats, has subsequently been adapted to mice, thus allowing the study of fibrogenesis by genetic approaches in transgenic mice. However, mouse Hsc isolation is commonly hampered by low yield and purity. Here we present an easy-to-perform protocol for high-purity and high-yield isolation of quiescent and activated Hscs in mice, based on retrograde pronase-collagenase perfusion of the liver and subsequent density-gradient centrifugation. We describe an optional add-on protocol for ultrapure Hsc isolation from normal and fibrotic livers via subsequent flow cytometric sorting, thus providing a validated method to determine gene expression changes during Hsc activation devoid of cell culture artifacts or contamination with other cells. the described isolation procedure takes ~4 h to complete.
IntroDuctIon
Fibrosis, defined as replacement of healthy parenchyma with extracellular matrix (ECM)-and myofibroblast-rich scar tissue, has been estimated to contribute to up to 45% of deaths in the developed world 1 . In the liver, fibrosis develops in response to hepatic injury, and it is common to virtually all liver diseases with hepatocellular damage 2 . Of note, liver fibrosis has been implicated in many of the grave complications of liver disease, such as the development of portal hypertension, progression to liver cirrhosis and the associated occurrence of hepatic failure, as well as the development of hepatocellular carcinoma 2, 3 . At a cellular level, multiple cell populations have been considered as contributors to fibrosis, including HSCs, portal fibroblasts, bone marrow-derived fibrocytes and hepatocytes 2, 4 . Recent cell fate tracing studies have positively identified HSCs as the dominant contributor to the myofibroblast pool, contributing 82-96% of myofibroblasts in various types of chronic liver diseases 5 . After liver injury, HSCs undergo a characteristic phenotypic change, and they differentiate from vitamin A-storing pericytes into ECM-producing myofibroblasts 6 . Although HSCs are the key contributors to liver fibrogenesis, HSC activation is modulated by multiple interactions with other hepatic cell types including hepatocytes, macrophages, endothelial cells, cholangiocytes and NK cells [7] [8] [9] [10] . Hence, fibrogenesis is viewed as a multicellular hepatic wound healing response with HSCs in its center, mediating the deposition of ECM and also providing contractile properties that regulate sinusoidal blood flow and portal pressure.
Methods to study HSC biology
The study of HSC biology may provide important mechanistic insights into the pathophysiology of liver fibrosis and hold the key to developing therapeutic approaches that block HSC activation and liver fibrosis 11 . HSC isolation allows the study of the pathways that regulate the activation of this key fibrogenic cell type in a well-defined context, and it has led to the identification of relevant regulatory pathways such as transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF) [12] [13] [14] .
Although HSC isolation was pioneered in rats 15, 16 , studying HSCs has shifted largely to mouse models in recent years owing to the availability of a wide range of genetic models. Until recently, HSC activation has commonly been studied in vitro using culture activation as a model for the activation process that HSCs undergo in vivo. Culture activation upregulates many of the key fibrogenic genes such as Col1a1 (encoding collagen, type 1, α1) and Acta2 (encoding α-smooth muscle actin), but it does not fully reproduce the gene expression pattern associated with the activation process observed in vivo 17, 18 . The unphysiological HSC activation process in culture is most likely caused by the lack of cell types that typically contribute to HSC activation, as well as the presence of an unphysiological environment in cell culture, such as an absence of cell-cell contact, the presence of FBS and plastic surfaces. Coculture with other cell types such as macrophages can overcome some, but not all, of these limitations 19 . Moreover, although the culture activation model is useful to test inhibitors of HSC activation, it has limited potential to study signals promoting HSC activation owing to the overwhelming effect of culture-induced activation that often overshadows the effect of specific profibrogenic mediators.
In vivo activation of HSCs provides a more physiological HSC activation model that is largely dictated by the choice of a physiological fibrosis model rather than by inherent limitations of the method. In vivo activation is not only helpful to understand gene expression patterns and pathways that contribute to HSC activation, but it may also be used to functionally investigate how pharmacologic or genetic interference with specific pathways affects HSC gene expression and activation status. Moreover, it provides a model to study events that occur during the regression of liver fibrosis, including the recently described ability of HSCs to deactivate and return to a nearly quiescent status 20, 21 . To achieve the best possible representation of in vivo HSC gene expression patterns, it is important to avoid artifacts by analyzing HSCs without plating and exposure to tissue culture, hence allowing a representative snapshot of molecular events that occur in HSCs within the liver. Application of the protocol The described HSC isolation protocol provides a basis for studying HSCs for a wide range of applications, including culture activation, coculture and functional interactions with other cell types, analysis of gene expression and epigenetic regulatory mechanisms, as well as proteomic, other omics and single-cell analyses. In comparison with portal vein perfusion procedures, which were originally developed for the isolation of rat HSCs 15 , the described retrograde perfusion technique via the inferior vena cava (IVC) not only achieves better hepatic perfusions and improved yield in mice but also provides a less technically challenging procedure that can be adapted by virtually every laboratory. A major advantage of this protocol is that, when using older mice and strains that yield high numbers of HSCs, one can isolate sufficient quantities of HSCs, typically in excess of two million HSCs per mouse, and therefore avoid the common practice of pooling of mice. Highyield isolations typically also reduce contamination of preparations with other cell types. As described in detail in this protocol, isolation of HSCs from fibrotic livers requires modification of enzyme concentrations and perfusion times.
Characterization of isolated HSCs
Increases in fibrogenic gene expression such as Col1a1, Acta2 or Lox (encoding lysyl oxidase), or decreases in Hhip (encoding hedgehog interacting protein) expression in the whole liver, are reflected by similar changes in gene expression in HSC isolates (Fig. 1a) , hence providing a snapshot of molecular events in this key fibrogenic cell population within the fibrotic liver. Increases in fibrogenic gene expression in the whole liver are the combined result of increased activation on a per-cell basis and of the expansion of the entire pool of HSC-derived myofibroblasts (which is not of relevance to the evaluation of mRNA expression in isolated HSCs). Therefore, normalizing fibrogenic gene expression using platelet-derived growth factor receptor-β (Pdgfr-β) mRNA, a marker for HSCs 22 that does not increase with HSC activation in our hands, provides a better estimate of HSC activation in the liver (Supplementary Fig. 1 ) than simply using 18S rRNA for normalization, as it accounts for the number of HSCs within the liver and thereby estimates the activation status per HSC (Fig. 1a) . Low-level background expression of fibrogenic genes by other cell types and the fact that HSC mRNA represents only ~1% of the liver's mRNA may contribute to a higher baseline level and lower induction (e.g., for Acta2, see Fig. 1a ) in the whole liver than in HSCs. Previous studies using single-cell quantitative PCR (qPCR) have shown that 95-100% of HSCs from CCl 4 -treated livers display increased expression of the activation marker Col1a1 (ref. 20) , suggesting that virtually all HSCs in the fibrotic liver activate. Although analysis of unplated HSCs from fibrotic livers provides a representative picture of molecular events, contamination with other cell types is observed when isolating HSCs by standard gradient centrifugation, especially in HSCs from fibrotic livers (Fig. 1b) . Contamination with other cell types may result in misinterpretation of data, in particular when the degree of contamination varies between different conditions (e.g., normal and fibrotic liver), when contamination is variable between HSC isolates and when sensitive techniques such as qPCR or microarray are used. For the investigation of HSC in vivo activation, we describe an optional add-on protocol, which allows the isolation of ultrapure unplated HSCs that can be combined with virtually any common fibrosis model in mice. FACS-based purification uses endogenous retinoid fluorescence of HSCs (using channels that are commonly used for the detection of DAPI, e.g., 405-407-nm laser for excitation and a 450/50-nm band-pass filter for detection) as a selection marker (Fig. 2a) . Retinoids are subject to rapid bleaching, and brief exposure of HSCs to UV light completely abrogates HSC fluorescence in the DAPI channel ( Supplementary  Fig. 2 ), providing evidence that this FACS-based method indeed relies on HSC-specific retinoid expression. Importantly, FACS purification significantly reduces the contamination with hepatocytes (determined by albumin (Alb) mRNA), endothelial cells (determined by von Willebrand factor (vWF) mRNA), macrophages (determined by EGF-like module-containing, mucin-like, hormone receptor-like 1 (Emr1) mRNA) and cholangiocytes (determined by keratin 19 (Krt19) mRNA; Fig. 2b) . Importantly, FACS purification of HSCs does not significantly alter the expression of HSC activation markers such as Col1a1, Acta2, Lox or Hhip (Fig. 2c) . Similarly, there is no significant alteration in gene expression of characteristic HSC-enriched marker genes (e.g., Lhx2 (encoding LIM homeobox 2), Lrat (encoding lecithin retinol acyltransferase), Pdgfrb, Hand2 (encoding heart and neural crest derivatives expressed 2) and Vim (encoding vimentin)), or genes that demonstrate the pronounced proliferation (Ccnb1 and Ccnb2 (encoding cyclin B1 and cyclin B2)) of HSCs in fibrotic livers ( Supplementary Fig. 3 ). Importantly, the FACS purification procedure itself also does not significantly alter the expression of activation genes and typical HSC-enriched genes, as determined by comparison with mock-sorted cells that were subjected to FACS purification without selection ( Fig. 2c and Supplementary  Fig. 3 ). Moreover, comparison of the FACS-sorted retinoid-high HSC population with the entire cell population excluded by this FACS procedure (termed 'retinoid-low cell population'-which also includes a minuscule fraction of autofluorescent cells with high retinoid and high FITC fluorescence) reveals that this retinoidlow population consists mainly of contaminating cells and only a few HSCs, as demonstrated by 18-693-fold higher levels of expression of hepatocyte-, macrophage-, cholangiocyte-and endothelial cell-specific genes, and a profoundly lower expression of characteristic HSC and HSC activation genes such as Pdgfrb, Lrat, Lhx2 and Hand2 ( Supplementary Fig. 4 ). Similar findings were made in the 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet model of biliary fibrosis, which shows similar levels of activation markers and HSC-enriched marker genes in FACS-sorted and mock-sorted HSCs, but significantly lower levels of contamination with other cell populations and a high level of non-HSC markers and low levels of HSC markers such as Pdgfrb in the retinoid-low population ( Supplementary Fig. 5 ).
In summary, the presented data confirm that retinoid-based FACS-based ultrapurification of HSCs significantly reduces artifacts due to contamination with other hepatic cell types, while preserving the expression pattern of characteristic HSC genes. We have also successfully applied this ultrapurification technique to other genetic, biliary and toxic fibrosis models including Mdr2 ko (Abcb4 −/− ) mice, mice with hepatocyte-specific TAK1 (Map3k7) deletion and mice undergoing bile duct ligation and thioacetamide-induced liver fibrosis (data not shown). Hence, the described easy-to-perform high-yield retrograde perfusion protocol, in combination with FACS-based ultrapurification, is applicable for HSC isolation in a wide range of experimentally induced liver fibrosis in mice.
Experimental design
All animal experiments included in this protocol should be performed and reported in adherence to the ARRIVE guidelines 23 . Before planning experiments involving HSC isolations, one should carefully consider different strains of mice and plan experiments to allow the use of aged mice. As such, BALB/c mice yield a substantially higher number of HSCs than C57Bl/6 mice, and older mice generally yield more HSCs than younger mice. When not working with transgenic mice, one can therefore consider ordering retired breeders, which are commonly available from commercial vendors. Although mice older than 12 weeks are desirable, advanced age (>6 months) in combination with previous exposure to breeder chow may lead to increased deposition of visceral fat, which makes difficult the precise cannulation and subsequent retrograde perfusion via the IVC, described in this protocol. However, in retired breeders that are maintained on normal chow diet, localization and perfusion of the IVC does not pose any problems. It is important to include appropriate controls-e.g., when analyzing HSC activation in fibrotic livers, one needs to include HSCs isolated from healthy mice as quiescent controls. Similarly, owing to the variability in fibrosis induction between individual mice, HSCs need to be isolated from an appropriate number of mice in each group to achieve sufficient power.
HSC isolation procedure. The isolation of HSCs from murine livers can be divided into three main sequential stages: (i) In situ n.s. n.s. n.s. n.s.
n.s. n.s. n.s. All data are shown as means ± sem. n = 5 control mice and n = 10 CCl 4 -treated mice. All animal procedures were approved by the Institutional Animal Care and Use Committee at Columbia University. ## P < 0.01 and ### P < 0.001 versus control mock-sorted and unsorted HSCs; *P < 0.05 and **P < 0.01 versus CCl 4 -treated mock-sorted and unsorted HSCs; n.s., nonsignificant.
pronase/collagenase perfusion of mouse liver; (ii) subsequent in vitro digestion; and (iii) density gradient-based separation of HSCs from other hepatic cell populations. The underlying principle is that HSCs can easily be separated from other cells based on their different densities owing to their abundance of lipid droplets.
The in situ perfusion of the mouse liver is the most crucial step of a successful HSC isolation. Temperature and enzyme concentrations are key determinants of enzymatic activity, and they are highly relevant for successful hepatic digestion. As such, it is important to adjust the temperature of the water bath and/or the length of connecting lines. The setup should be adjusted to achieve a temperature of ~29.5 °C at the end of the line-i.e., where solutions enter the IVC. Therefore, it is crucial to prewarm the pronase and collagenase solutions to 42 °C. To ensure constant temperature during in vivo digestion, a heat lamp should be placed above the mouse and switched on once the perfusion with pronase solution is started. A key step in the procedure is successful cannulation of the IVC with an IV catheter ( Fig. 3a;  Supplementary Video 1) , and to then stabilize the perfusion setup to avoid dislocation of the catheter during the perfusion. Retrograde liver perfusion is only achieved after cutting the portal vein, which allows solutions to perfuse the liver and exit via the portal vein. The portal vein becomes distended after the pump has been started, and it is therefore easy to locate and cut ( Fig. 3b and Supplementary Video 2) . Finally, clamping the IVC above the diaphragm directs all solutions through the liver and prevents the perfusion of other organs (Fig. 3b and  Supplementary Video 2) . The initial EGTA solution flushes out blood and thus avoids contamination with red blood cells and clotting of hepatic vessels, which may result in incomplete perfusion and digestion. Successful perfusion can be easily observed by swelling of the liver and a change to a pale color after the portal vein has been severed. Subsequently, perfusion with pronase solution is performed for 5 min, followed by collagenase perfusion for 7 min to achieve digestion of the liver (Fig. 3c) . Air bubbles are caught in a trap; hence, switching from one solution to the other does not pose a problem in this regard.
After the in situ digestion, the liver is carefully removed and minced under sterile conditions (Fig. 3d and Supplementary  Video 3) . The minced liver is further digested in vitro with prewarmed pronase/collagenase solution (Fig. 3e) . The liver cell suspension is then filtered through a 70-µm cell strainer to eliminate undigested tissue remnants, and it is washed to remove excess digestion enzymes (Fig. 3f) . The final step of the isolation procedure is a density gradient centrifugation including collection and counting of HSCs. After resuspending the liver cell suspension with density gradient medium, it is important to very slowly add the density gradient-free medium on top of the cell-density gradient solution (Fig. 3g and Supplementary  Video 4) . Similarly, it is important to centrifuge the gradient without brake so that the HSC-containing layer on top of the gradient is not disrupted (Fig. 3g) . After collecting HSCs (Fig. 3h and Supplementary Video 5) and after the final centrifugation (Fig. 3i) , the purity of HSC isolation can easily be assessed by fluorescence microscopy by calculating the ratio of retinoidpositive HSCs to all cells (Fig. 1b) . As shown above, real-time qPCR provides a more sensitive method for assessing contamination with specific cell types. It should be noted that the percentage of RNA contamination does not equal the percentage of cell contamination, as non-HSC populations, particularly hepatocytes, often express markedly higher amounts on a per-cell basis of total RNA and of specific RNAs used for the normalization of qPCR, such as 18S.
Isolating HSCs from fibrotic mice. The procedure for isolating HSCs from fibrotic mouse livers (Supplementary Methods) is technically similar to isolating HSCs from untreated mice. The only modification is the amount of collagenase added to the collagenase solution and a prolonged perfusion in models with severely fibrotic livers such as the Mdr2 ko mice. As HSCs lose some of their retinoid-containing lipid droplets (loss of all droplets virtually never occurs in experimental models of fibrosishence, isolation of activated HSCs is therefore possible in almost all models), the relative purity decreases and there may also be a decrease in vitamin A fluorescence when performing FACS sorting of cells (see below). Isolation of HSCs from fibrotic livers is usually prone to more contamination from other cell populations, in particular hepatocytes or F4/80-positive Kupffer cells (Figs. 1 and 2) . Hence, a second purification via FACS sorting (Fig. 2) is recommended for most applications involving HSCs isolations from fibrotic livers, as discussed below.
Isolating HSCs via FACS.
Cell sorting by FACS can be used to reduce contamination with cell types other than HSCs, and it is especially relevant when analyzing gene expression patterns. Although it is, in principle, possible to sort HSCs directly from unpurified liver cell suspensions, it may take several hours as HSCs represent only a small fraction. In contrast, FACS sorting of gradient-purified HSCs typically allows sorting within ~20 min per mouse, and it also results in higher purity owing to the application of two subsequent purification methods. For sorting, HSCs are resuspended in phenol red-free medium containing 1% (vol/ vol) FBS. The characteristic HSC-specific vitamin A fluorescence allows the purification of HSCs to >99% purity, using a 405-407-nm laser for excitation and a 450/50-nm band-pass filter for detection ( Fig. 2a and Supplementary Fig. 2b) . Enrichment of HSCs with concomitant reduction of contaminating cell populations has been previously reported by a scatter-based FACS sorting method for rat HSCs 24 . HSCs, even when isolated from fibrotic livers, are typically seen as a separate retinoid-positive population in the violet FACS channel (Fig. 2a) . Studies in Lrat-deficient mice that lack typical retinoid-rich lipid droplets in HSCs have indeed confirmed that retinoid storage and HSC activation are two functionally separate responses 25 , and HSC activation does not necessarily translate into immediate loss of HSC retinoid stores. Only in severe and longstanding fibrosis is vitamin A content so low that the HSC population overlaps other cell populations that have high autofluorescence. In this case, either a selection of cells with the highest vitamin A fluorescence can be used (usually achieving acceptable HSC purity) or additional methods such as genetic labeling of HSCs 5 may be required.
Limitations
Although the described protocol typically yields large quantities of pure HSCs, there are limitations to be considered. As discussed, yield will be lower in C57Bl/6 mice, especially when younger mice are used. In obese mice, excess peritoneal fat may obscure access to the IVC and make it difficult to cannulate. In this particular setting, perfusion via the portal vein can be considered. In addition, excessive hepatic steatosis may result in increased hepatocyte contamination, as steatotic hepatocytes acquire a density more similar to HSCs. Furthermore, isolation procedures expose HSCs to significant stress such as enzymatic digestions, centrifugation forces and loss of cell-cell communication. These limitations have to be considered when analyzing rapid signaling events such as immediate-early gene expression, transcription factors or kinase activation-which may be activated as a result. Comparison between cell isolates that both underwent the same isolation procedure (e.g., comparing FACS-purified HSCs from normal and fibrotic livers) will circumvent this problem, as most changes will occur in both conditions and therefore not affect the comparison. Similarly, digestion procedures may temporarily decrease the expression of cell surface proteins and hamper flow cytometric analysis of surface markers. Finally, the described add-on FACS sorting protocol can reduce the ability of HSCs to attach to cell culture plates and to undergo culture activation, in particular if one does not optimize cell collection and use low-pressure sorting procedures. As discussed, FACS-based ultrapurification reduces the overall yield. Depending on how stringently the gates are set, one can either minimize or even completely exclude contamination by other cells by very selective gating on HSCs at the cost of reduced yield, or increase the yield by less-stringent gating at the cost of slightly increased contamination with other cells. Although our data clearly show that retinoid-based HSC sorting maintains HSC expression and activation markers and reduces contamination with other cell types, we cannot completely rule out that the retinoid-low HSC population excluded by this method contains a small subset of HSCs with yet-unrecognized functions that are different from the main population of retinoid-high HSCs. DNase I Dissolve 100 mg of DNase I in 50 ml of GBSS/B by gently pipetting, as DNase I is susceptible to physical denaturation. The prepared DNase I should be divided into aliquots and stored at −20 °C until use. Avoid repeated freezing and thawing, and the aliquots should be stable for up to 18 months. 
EGTA solution
Prepare aliquots of 35 ml of EGTA solution per mouse.
1|
Anesthetize the mouse according to your institution's approved animal protocol; we perform anesthesia with the inhalation of isoflurane (1-3%, wt/vol). ! cautIon All animal experiments must be performed in accordance with relevant institutional guidelines and regulations.
2|
Fix the mouse by using tape to attach the upper and lower extremities on a dissecting board, and then perform a laparotomy to expose the liver and the IVC.
3|
Move the visceral organs to the right side to expose the IVC, and then cannulate the IVC with a 22-gauge catheter.
4|
Connect the catheter to the perfusion line and stabilize the setup to avoid dislocation of the catheter ( Fig. 3a; supplementary Video 1).  crItIcal step Proper cannulation of the IVC is crucial for a successful perfusion. Ensure that the catheter is correctly inserted in the IVC by aspirating with a syringe to see blood flow. Make certain that no bubbles are introduced by filling the catheter with EGTA solution before connecting the perfusion line. Work quickly to avoid delay in perfusion in order to prevent thrombosis, which results in improper digestion.
? trouBlesHootInG 5| Start the pump to begin perfusion of the mouse liver with EGTA solution.
6|
Wait until the portal vein becomes distended, and then cut the portal vein.
7| Cut through the diaphragm and place the clamp on the IVC above the diaphragm to ensure retrograde perfusion of the liver ( Fig. 3b; supplementary Video 2). If puncture and initial perfusion were performed adequately, the liver should be pale after severing the portal vein and clamping the suprahepatic IVC.
? trouBlesHootInG 8| Perfuse the liver with the EGTA for a total of 1-2 min. Switch on the heat lamp directed toward the mouse liver.
9|
Switch from the EGTA solution to the pronase solution (Fig. 3c) and perfuse the liver for 5 min (Fig. 3c) .
10|
Change from the pronase solution to the collagenase solution and perfuse the liver for 7 min. Remove the perfusion line out of the collagenase solution and continue perfusing the liver until the perfusion line is empty (Fig. 3c) .  crItIcal step Perfuse the liver for 9 min instead of 7 min when isolating HSCs from 2-month-old Mdr2 ko mice.
11|
Remove the catheter from the IVC. Explant the liver into a sterile Petri dish containing 5 ml of the pronase/collagenase solution (Fig. 3d) .
12| Gently mince the liver under a sterile cell-culture hood with forceps ( Fig. 3d; supplementary Video 3) . The liver should almost be completely fluid, without chunks of tissue after successful in situ perfusion.
In vitro digestion • tIMInG 50 min 13| Add 1% DNase to the prewarmed pronase/collagenase solution, and then transfer the minced liver into the prewarmed pronase/collagenase solution containing 1% (vol/vol) DNase; place it on the stir plate (40 °C, stirring level 1) for 25 min (Fig. 3e) .  crItIcal step Do not exceed 25 min to prevent loss of cell viability owing to overdigestion. However, if in situ enzyme perfusion did not thoroughly digest the liver, prolong the in vitro digestion procedure by at most 10 min.
? trouBlesHootInG
14|
Filter the digested mouse liver through a 70-µm cell strainer into a 50-ml Falcon tube (Fig. 3e) .
15|
Centrifuge the mixture at 580g for 10 min (4 °C). Aspirate the supernatant until 10 ml remains in the tube, and then add 120 µl of DNase I and resuspend with a 10-ml pipette. Fill it up to 50 ml with GBSS/B and resuspend to wash the cells, and then centrifuge again at 580g for 10 min at 4 °C (Fig. 3f) .
Density gradient-mediated separation • tIMInG 60 min 16| Aspirate the supernatant until 10 ml remains in the tube, add 120 µl of DNase I and resuspend with a 10-ml pipette. Fill up to 32 ml with GBSS/B and then add 16 ml of Nycodenz solution. Mix thoroughly by gently pipetting or inverting the tube, and then pipette 12 ml of cell-Nycodenz suspension into each of the four 15-ml Falcon tubes. Tilt the tubes to moisten the walls to facilitate the overlay.
17|
Gently overlay with cell-Nycodenz suspension with 1.5 ml of GBSS/B using a 3-ml syringe with a 26-gauge needle attached ( Fig. 3g; supplementary Video 4) . Centrifuge the suspension at 1,380g for 17 min (4 °C) without brake (Fig. 3g) .  crItIcal step Make sure to overlay the GBSS/B very slowly and gently above the cell-Nycodenz suspension to create a discontinuous gradient. A clear separation should be observed between the cell-Nycodenz suspension and GBSS/B.  crItIcal step Ensure that the deceleration setting is set to 0 or 'no brake'; otherwise, the discontinuous gradient will fail to collect HSCs in the interface. ? trouBlesHootInG 18| At the end of centrifugation, the HSCs are visible as a thin white layer in the interface between the cell-Nycodenz solution and the overlay with GBSS/B (Fig. 3h) . Use a 5-ml pipette to collect the cells and transfer them into a new 50-ml Falcon tube ( Fig. 3h; supplementary Video 5). Repeat the procedure for all four 15-ml Falcon tubes.
19|
Add GBSS/B to fill up the Falcon tube to 50 ml, and then gently pipette to resuspend the collected HSCs; centrifuge at 580g for 10 min at 4 °C (Fig. 3i) .
20| Aspirate the supernatant and resuspend the cell pellet in DMEM with 10% FBS for counting if it is to be used immediately for cell culture. If subsequent FACS sorting is planned, proceed to the next step. ? trouBlesHootInG (optional) secondary purification of isolated Hscs by Facs • tIMInG 40 min 21| If an ultrapure population of HSCs is desired, collect the cell pellet and resuspend it in an appropriate volume of DMEM (without phenol red) with 1% (vol/vol) FBS to achieve 10 7 cells per ml (use at least a volume of 300 µl).  crItIcal step Ensure that the cells are protected from light to prevent photobleaching of retinoid fluorescence.
22|
Use a 405-407-nm laser for excitation and a 450/50-nm band-pass filter on a cell sorter for retinoid detection.
To sort out retinoid-positive HSCs, three gating steps are typically performed. The first gate should be set in the forward and sideward scatter (supplementary Fig. 2b ; left FACS plots), followed by a gate to exclude cell duplets (supplementary Fig. 2b ; right FACS plots). Next, cells are analyzed by the violet A channel in combination with either the FITC channel or the forward scatter, revealing cells according to their retinoid content (Fig. 2a) 
antIcIpateD results
As previously mentioned, isolation from mice of the BALB/c background usually results in higher HSC yield compared with isolation from other strains including C57Bl/6 and transgenic mice of mixed background. However, besides the genetic background, age is the most crucial determinant of yield and purity. From experience, mice younger than 8 weeks of age yield fewer than 0.5-1 million cells per mouse, and they may require pooling of multiple mice for a single experiment. Although isolations of HSCs from mice between 8 and 12 weeks of age typically yield 1-2 million HSCs per mouse, mice older than 12 weeks or retired breeders (usually 7-9 months of age when ordered from Taconic or Jackson Laboratories) allow isolation of 2-3 million HSCs. This protocol achieves ~90-98% purity from isolations from normal livers in retired breeders and 80-90% purity when isolating from injured/fibrotic livers. Consequently, if an ultrapure HSC population is desired from mice with liver injury, the add-on FACS protocol is highly recommended to eliminate contamination from non-HSC hepatic cells. However, it should be noted that FACS sorting will improve purity but decrease yield, depending on the stringency of the gating and selection process. The average yield of RNA from 1 million HSCs ranges from 0.8 to 1.2 µg, with activated cells generally yielding more RNA. 
